No Data
No Data
Shenzhen Hepalink Pharmaceutical Group: 2024 Interim Performance Forecast
Shenzhen Hepalink Pharmaceutical's Profit to Soar Nearly 500% in H1
Shenzhen Hepalink Pharmaceutical Group (HKG:9989, SHE:002399) expects a 421-496% boost in attributable profit for the six months ended June 30 to between around 642.3 million yuan and 734.8 million
Shenzhen Hepalink Sees Soaring H1 2024 Profits
Express News | Shenzhen Hepalink Pharmaceutical Sees Hy Net Profit Attributable Between RMB642.28 Million to RMB734.82 Million
HEPALINK: POSITIVE PROFIT ALERT - ANNOUNCEMENT FOR THE ESTIMATED 2024 INTERIM RESULTS
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
No Data